News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AiCuris And Merck & Co., Inc. (MRK) Announce Publication In New England Journal Of Medicine Of Phase 2 Clinical Trial Results Of Investigational Antiviral Agent Letermovir In Bone Marrow Transplant Patients


5/8/2014 10:54:18 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WUPPERTAL, Germany & WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--AiCuris and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from a Phase 2 clinical trial evaluating the safety and efficacy of letermovir, an investigational, oral antiviral agent for the prevention of human cytomegalovirus (CMV) infection in patients receiving bone marrow transplant. The results published in the latest issue of the New England Journal of Medicine (NEJM) show that letermovir in CMV-seropositive allogeneic human blood precursor cell recipients (bone marrow transplant patients) met the study’s two primary efficacy endpoints. Merck plans to conduct a Phase 3 trial of letermovir, also known as AIC246 or MK-8228, starting in the first half of 2014.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES